Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Arcturus Therapeutics Holdings Inc. (ARCT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G/A STATE STREET CORP reports a 6.3% stake in AMENDED FILING ARCTURUS THERAPEUTICS HOLDINGS INC
10/04/2023 4 Chivukula Pad (Chief Scientific Officer & COO) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Sold 5,000 shares @ $25.6123, valued at $128.1k
10/02/2023 144 Form 144 - Report of proposed sale of securities:
09/26/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA Therapeutic to Treat Cystic Fibrosis"
08/17/2023 4 SASSINE ANDY (CFO) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Granted 1,223 shares @ $17.374, valued at $21.2k
08/14/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government"
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "ARCTURUS THERAPEUTICS HOLDINGS INC. AMENDMENT NO. 1 TO Controlled Equity Offering SM Sales Agreement August 7, 2023 CANTOR FITZGERALD & CO. 499 Park Avenue 10022 WELLS FARGO SECURITIES, LLC 30 Hudson Yards New York, New York 10001 William Blair & Company, L.L.C.",
"Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress"
08/07/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/03/2023 4 Chivukula Pad (Chief Scientific Officer & COO) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Sold 5,000 shares @ $34.91, valued at $174.6k
08/03/2023 4 Markels John (Director) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Granted 11,869 options to buy @ $34.92, valued at $414.5k
Granted 3,131 restricted stock units @ $0
08/03/2023 4 FARRELL PETER C (Director) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Granted 11,869 options to buy @ $34.92, valued at $414.5k
Granted 3,131 restricted stock units @ $0
08/03/2023 4 Marantz Jing L. (Director) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Granted 11,869 options to buy @ $34.92, valued at $414.5k
Granted 3,131 restricted stock units @ $0
08/03/2023 4 HOLMES EDWARD W (Director) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Granted 11,869 options to buy @ $34.92, valued at $414.5k
Granted 3,131 restricted stock units @ $0
08/03/2023 4 BARLOW JAMES F (Director) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Granted 11,869 options to buy @ $34.92, valued at $414.5k
Granted 3,131 restricted stock units @ $0
08/03/2023 4 Marquet Magda (Director) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Granted 11,869 options to buy @ $34.92, valued at $414.5k
Granted 3,131 restricted stock units @ $0
08/01/2023 144 Form 144 - Report of proposed sale of securities:
07/18/2023 4 Chivukula Pad (Chief Scientific Officer & COO) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Sold 25,000 shares @ $35.01, valued at $875.3k
07/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/14/2023 144 Form 144 - Report of proposed sale of securities:
07/14/2023 144 Form 144 - Report of proposed sale of securities:
07/14/2023 8-K Regulation FD Disclosure  Interactive Data
07/07/2023 4 Chivukula Pad (Chief Scientific Officer & COO) has filed a Form 4 on Arcturus Therapeutics Holdings Inc.
Txns: Sold 5,000 shares @ $28.75, valued at $143.8k
06/30/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Additional Application for Booster Dose of ARCT-154, Self-Amplifying mRNA Vaccine against COVID-19, Submitted in Japan"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress"
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/28/2023 8-K Quarterly results
04/21/2023 8-K Quarterly results
04/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy